Reported 1 day ago
Iovance Biotherapeutics experienced a nearly 6% drop in its stock value following an analyst downgrade from UBS's David Dai, who revised his recommendation from 'buy' to 'neutral' and lowered his price target from $17 to $2. The downgrade came after the company's recent quarterly earnings report, which revealed disappointing sales for its advanced melanoma drug, Amtagvi, and raised concerns over patient selection and commercialization pace.
Source: YAHOO